NCT01259115View on ClinicalTrials.gov

Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

June 30, 2003

Study Completion Date

June 30, 2003

Conditions
Healthy
Interventions
DRUG

Buprenorphine transdermal patch

Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.

DRUG

Ketoconazole tablet

Ketoconazole 200 mg tablets taken orally twice daily.

DRUG

Placebo to match ketoconazole tablet

Placebo to match ketoconazole 200 mg tablets taken orally twice daily.

Trial Locations (1)

70119

Clinical Research Center, New Orleans

All Listed Sponsors
lead

Purdue Pharma LP

INDUSTRY

NCT01259115 - Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole | Biotech Hunter | Biotech Hunter